Literature DB >> 23355455

Gene therapy clinical trials worldwide to 2012 - an update.

Samantha L Ginn1, Ian E Alexander, Michael L Edelstein, Mohammad R Abedi, Jo Wixon.   

Abstract

To date, over 1800 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical trials from official agency sources, published literature, conference presentations and posters kindly provided to us by individual investigators or trial sponsors. This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of our June 2012 update, we have entries on 1843 trials undertaken in 31 countries. We have analysed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and which genes have been transferred. Details of the analyses presented, and our searchable database are available on The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. We also provide an overview of the progress being made in clinical trials of gene therapy approaches around the world and discuss the prospects for the future.
Copyright © 2013 John Wiley & Sons, Ltd.

Mesh:

Year:  2013        PMID: 23355455     DOI: 10.1002/jgm.2698

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  220 in total

1.  Modified Genomic Sequencing PCR Using the MiSeq Platform to Identify Retroviral Integration Sites.

Authors:  Dustin T Rae; Casey P Collins; Jonah D Hocum; Diana L Browning; Grant D Trobridge
Journal:  Hum Gene Ther Methods       Date:  2015-10-20       Impact factor: 2.396

2.  Horizontal gene transfer from macrophages to ischemic muscles upon delivery of naked DNA with Pluronic block copolymers.

Authors:  Vivek Mahajan; Zagit Gaymalov; Daria Alakhova; Richa Gupta; Irving H Zucker; Alexander V Kabanov
Journal:  Biomaterials       Date:  2015-10-09       Impact factor: 12.479

3.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

4.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

5.  Orthopedic cellular therapy: An overview with focus on clinical trials.

Authors:  Moon Jong Noh; Kwan Hee Lee
Journal:  World J Orthop       Date:  2015-11-18

Review 6.  Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

Authors:  Andrew B Hill; Mingfu Chen; Chih-Kuang Chen; Blaine A Pfeifer; Charles H Jones
Journal:  Trends Biotechnol       Date:  2015-12-23       Impact factor: 19.536

7.  Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.

Authors:  Jianzhong Ai; Phillip W L Tai; Yi Lu; Jia Li; Hong Ma; Qin Su; Qiang Wei; Hong Li; Guangping Gao
Journal:  Prostate       Date:  2017-07-20       Impact factor: 4.104

Review 8.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

9.  Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2015 Jun-Jul       Impact factor: 4.565

10.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.